ADC Therapeutics

News

ADC Therapeutics slumps on cancer drug safety scare

Shares in ADC Therapeutics fell more than 50% after a non-Hodgkin lymphoma trial showed more deaths with its Zynlonta drug compared to a control.

R&D

Partner Content

15th World ADC San Diego 2024

The World’s Largest, Longest-Standing & Most Comprehensive Antibody-Drug Conjugate Conference

News

ADC pauses Zynlonta lymphoma trial after deaths

Shares in ADC Therapeutics fell sharply after the company said it had suspended a trial of Zynlonta in previously untreated diffuse large B-cell lymphoma (DLBCL) patients

News

Changing Faces: biopharma hires from November 2022

The month of November saw a number of notable hires and personnel moves in biotech and

News

FDA blocks early filing for ADC drug, signalling tougher sta...

ADC Therapeutics has said it will not seek accelerated approval of its Hodgkin lymphoma drug camidanlumab tesirine (cami) based on phase 2 results, as the FDA will not review it unless a co

News